Maa: Etelä-Afrikka
Kieli: englanti
Lähde: South African Health Products Regulatory Authority (SAHPRA)
Adcock
INDICATIONS [/za_112.html#1] [/za_112.html#1] [/za_112.html#1] CONTRA-INDICATIONS [/za_112.html#1] [/za_112.html#1] DOSAGE [/za_112.html#1] [/za_112.html#1] SIDE-EFFECTS [/za_112.html#1] [/za_112.html#1] [/za_112.html#1] PREGNANCY [/za_112.html#1] [/za_112.html#1] OVERDOSE [/za_112.html#1] IDENTIFICATION [/za_112.html#1] [/za_112.html#1] PATIENT INFORMATION ADCO-LINCTOPENT SYRUP SCHEDULING STATUS: S2 PROPRIETARY NAME (and dosage form): ADCO-LINCTOPENT SYRUP COMPOSITION: Each 5 mL contains: BROMHEXINE hydrochloride 4 mg; ORCIPRENALINE sulphate 5 mg. PRESERVATIVES: Methyl parahydroxybenzoate 0,05% m/v, propyl parahydroxybenzoate 0,01% m/v. Alcohol free. Sugar free. PHARMACOLOGICAL CLASSIFICATION: A.10.1 Medicines acting on the respiratory system. Anti-tussives and expectorants. PHARMACOLOGICAL ACTION: ADCO-LINCTOPENT SYRUP has mucolytic and bronchodilatory properties. INDICATIONS: ADCO-LINCTOPENT SYRUP is indicated for cough associated with wheeziness (bronchospasm) and tenacious phlegm (sputum). CONTRA-INDICATIONS: ADCO-LINCTOPENT SYRUP is contra-indicated in patients with known hypersensitivity to sympathomimetic amines or any of the other ingredients; hypertrophic obstructive cardiomyopathy; and tachyarrhythmia. Sympathomimetics, such as orciprenaline sulphate, may interact with monoamine oxidase inhibitors (MAOI), and therefore ADCO-LINCTOPENT SYRUP should not be given to patients receiving such treatment or within 14 days of MAOI treatment termination. Safety in pregnancy and lactation has not been established. DOSAGE AND DIRECTIONS FOR USE: ADULTS AND CHILDREN OVER 12 YEARS: 10 - 20 mL three times daily. CHILDREN 3 TO 12 YEARS: 5 - 10 mL three times daily. CHILDREN 1 TO 3 YEARS: 2,5 - 5 mL three times daily. INFANTS: 2,5 mL three times daily. Do not exceed the re Lue koko asiakirja